Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder
-
Shima Sahraian
,
Mohammad Babashams
,
Pouria Reza-Soltani
,
Hossein Najmabadi
,
Kimia Kahrizi
,
Sahel Hemmati Gorgani
Abstract
Objective: Several studies have implicated the 5-HTTLPR polymorphism in treatment outcomes of selective serotonin re-uptake inhibitors in patients with major depression. The aim of this study was to examine the association between polymorphism in the serotonin transporter gene and citalopram effectiveness in Iranian patients suffering from major depressive disorder (MDD).
Methods: The sample consisted of 104 patients, with Fars ethnic background, who were diagnosed according to DSM-IV-TR criteria. Beck Depression inventory was used to evaluate the severity of the symptoms during the follow-up, and to determine clinical response of the patients at 4th and 8th week, respectively.
Results: Our results showed a correlation between the genotype and response to antidepressant drug citalopram, (odds ratios for L/S and L/L were 3.90 (95 percent CI: 1.29- 11.80) and 1.90 (95 percent CI: 0.72-5.08), respectively).
Conclusion: In conclusion, our results reveal that genetic variation of serotonin transporter is involved in clinical remission of major depressive episodes in Iranian patients after citalopram treatment.
Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in Affective Disorders. Eur J Pharmacol 2002; 438: 117-128.
Veenstra-VanderWeele J, Anderson GM, Cook EH, Jr. Pharmacogenetics and the Serotonin System: Initial Studies and Future Directions. Eur J Pharmacol 2000; 410: 165-181.
Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. Biol Psychiatry 2010; 67: 133-138.
Sullivan PF, Neale MC, Kendler KS. Genetic Epidemiology of Major Depression: Review and Meta-Analysis. Am J Psychiatry 2000; 157: 1552-1562.
Murray CJ, Lopez AD. Evidence-Based Health Policy--Lessons from the Global Burden of Disease Study. Science (New York, N.Y.) 1996; 274: 740-743.
Serretti A, Artioli P. The Pharmacogenomics of Selective Serotonin Reuptake Inhibitors. Pharmacogenomics J 2004; 4: 233-244.
Keers R, Uher R. Gene-Environment Interaction in Major Depression and Antidepressant Treatment Response. Curr Psychiatry Rep 2012; 14: 129-137.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in Star*D: Implications for Clinical Practice. Am J Psychiatry 2006; 163: 28-40.
Brigitta B. Pathophysiology of Depression and Mechanisms of Treatment. Dialogues Clin Neurosci 2002; 4: 7-20.
10-Sackeim HA. The Definition and Meaning of Treatment-Resistant Depression. J Clin Psychiatry 2001; 62 Suppl 16: 10-17.
Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D, et al. A Novel Functional Polymorphism within the Promoter of the Serotonin Transporter Gene: Possible Role in Susceptibility to Affective Disorders. Mol Psychiatry 1996; 1: 453-460.
Kato M, Serretti A. Review and Meta-Analysis of Antidepressant Pharmacogenetic Findings in Major Depressive Disorder. Mol Psychiatry 2010; 15: 473-500.
Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, et al. Antidepressant- and Cocaine-Sensitive Human Serotonin Transporter: Molecular Cloning, Expression, and Chromosomal Localization. Proc Natl Acad Sci U S A 1993; 90: 2542-2546.
Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P, et al. Gene-Environment Interaction Analysis of Serotonin System Markers with Adolescent Depression. Mol Psychiatry 2004; 9: 908-915.
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region. Science (New York, N.Y.) 1996; 274: 1527-1531.
Uher R, McGuffin P. The Moderation by the Serotonin Transporter Gene of Environmental Adversity in the Aetiology of Mental Illness: Review and Methodological Analysis. Mol Psychiatry 2008; 13: 131-146.
Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, et al. Factors Affecting Fluvoxamine Antidepressant Activity: Influence of Pindolol and 5-Httlpr in Delusional and Nondelusional Depression. Biol Psychiatry 2001; 50: 323-330.
Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, et al. Organization of the Human Serotonin Transporter Gene. J Neural Transm Gen Sect 1994; 95: 157-162.
Uher R, McGuffin P. The Moderation by the Serotonin Transporter Gene of Environmental Adversity in the Aetiology of Mental Illness: Review and Methodological Analysis. Molecular psychiatry 2008; 13: 131-146.
Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of Serotonin-Related Genes in Antidepressant Response. Mol Psychiatry 2004; 9: 879-889.
Kupfer DJ, Frank E, Phillips ML. Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives. Lancet 2012; 379: 1045-1055.
Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-Analysis of Serotonin Transporter Gene Promoter Polymorphism (5-Httlpr) Association with Selective Serotonin Reuptake Inhibitor Efficacy in Depressed Patients. Mol Psychiatry 2007; 12: 247-257.
Porcelli S, Fabbri C, Serretti A. Meta-Analysis of Serotonin Transporter Gene Promoter Polymorphism (5-Httlpr) Association with Antidepressant Efficacy. Eur Neuropsychopharmacol 2012; 22: 239-258.
Taylor MJ, Sen S and Bhagwagar Z. Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region. Biol Psychiatry 2010; 68: 536-543.
Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, et al. Slc6a4 Variation and Citalopram Response. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2009; 150B: 341-351.
Hiroi R, McDevitt RA, Neumaier JF. Estrogen Selectively Increases Tryptophan Hydroxylase-2 Mrna Expression in Distinct Subregions of Rat Midbrain Raphe Nucleus: Association between Gene Expression and Anxiety Behavior in the Open Field. Biol Psychiatry 2006; 60: 288-295.
Wissink S, van der Burg B, Katzenellenbogen BS, van der Saag PT. Synergistic Activation of the Serotonin-1a Receptor by Nuclear Factor-Kappa B and Estrogen. Biol Psychiatry (Baltimore, Md.) 2001; 15: 543-552.
Lu NZ, Eshleman AJ, Janowsky A, Bethea CL. Ovarian Steroid Regulation of Serotonin Reuptake Transporter (Sert) Binding, Distribution, and Function in Female Macaques. Molecular psychiatry 2003; 8: 353-360.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The Uku Side Effect Rating Scale. A New Comprehensive Rating Scale for Psychotropic Drugs and a Cross-Sectional Study of Side Effects in Neuroleptic-Treated Patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100.
Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse Reactions to Antidepressants. The British journal of psychiatry: the journal of mental science 2009; 195: 202-210.
Miller SA, Dykes DD, Polesky HF. A Simple Salting out Procedure for Extracting DNA from Human Nucleated Cells. Nucleic acids research 1988; 16: 1215.
Bellivier F, Henry C, Szoke A, Schurhoff F, Nosten-Bertrand M, Feingold J, et al. Serotonin Transporter Gene Polymorphisms in Patients with Unipolar or Bipolar Depression. Neurosci Lett 1998; 255: 143-146.
Du L, Bakish D, Hrdina PD. Gender Differences in Association between Serotonin Transporter Gene Polymorphism and Personality Traits. Psychiatr Genet 2000; 10: 159-164.
Weinshilboum R. Inheritance and Drug Response. N Engl J Med 2003; 348: 529-537.
Weiss LA, Abney M, Cook EH, Jr. and Ober C. Sex-Specific Genetic Architecture of Whole Blood Serotonin Levels. Am J Hum Genet 2005; 76: 33-41.
Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The Serotonin Transporter Polymorphism, 5httlpr, Is Associated with a Faster Response Time to Sertraline in an Elderly Population with Major Depressive Disorder. Psychopharmacology 2004; 174: 525-529.
Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the Promoter of the Serotonin Transporter Gene and Antidepressant Efficacy of Fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism within the Promoter of the Serotonin Transporter Gene. J Clin Psychopharmacol 2000; 20: 105-107.
Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, et al. Association between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients with Major Depression. Arch Gen Psychiatry 2007; 64: 783-792.
Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. Serotonin Transporter Gene Polymorphism and Antidepressant Response. Neuroreport 2000; 11: 215-219.
Crawford AA, Lewis G, Lewis SJ, Munafo MR. Systematic Review and Meta-Analysis of Serotonin Transporter Genotype and Discontinuation from Antidepressant Treatment. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2012.
Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association Study of the Serotonin Transporter Promoter Polymorphism and Symptomatology and Antidepressant Response in Major Depressive Disorders. Mol Psychiatry 2002; 7: 1115-1119.
Baily MA, Bottrell M, Lynn J, Jennings B, Hastings C. The Ethics of Using Qi Methods to Improve Health Care Quality and Safety. Hastings Cent Rep 2006; 36: S1-40.
Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, et al. Polymorphism of the 5-Ht Transporter and Response to Antidepressants: Randomised Controlled Trial. Br J Psychiatry 2011; 198: 464-471.
| Files | ||
| Issue | Vol 8 No 2 (2013) | |
| Section | Articles | |
| Keywords | ||
| 5-HTTLPR genotype Iran Major depressive disorder association study citalopram response | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
